{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:36:55Z","timestamp":1791059815540,"version":"4.1.0"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Spero Therapeutics"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,6,17]]},"abstract":"<jats:p>\n            Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an orally available prodrug of tebipenem (TBP), a carbapenem with\n            <jats:italic>in vitro<\/jats:italic>\n            activity against multidrug-resistant Gram-negative pathogens. This study evaluated the effects of single therapeutic and supratherapeutic doses of TBP-PI-HBr on the heart rate-corrected QT interval (QTc) by assessing the concentration-QT interval relationship using exposure-response modeling.\n          <\/jats:p>","DOI":"10.1128\/aac.00145-21","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T14:31:26Z","timestamp":1618583486000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT\/QTc Intervals in Healthy Subjects"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-5126","authenticated-orcid":true,"given":"Vipul K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maier","sequence":"additional","affiliation":[{"name":"Maier Metrics and Associates, LLC, Falmouth, Maine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6133-9057","authenticated-orcid":true,"given":"Paul","family":"Eckburg","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Morelli","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lei","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Jain","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Manyak","sequence":"additional","affiliation":[{"name":"Ribon Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Melnick","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0706513"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12054"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/508873"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/11531850-000000000-00000"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.34141"},{"key":"e_1_3_2_7_2","volume-title":"E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non antiarrhythmic drugs: questions and answers (R3): guidance for industry.","author":"Food and Drug Administration","year":"2017","unstructured":"Food and Drug Administration. 2017. E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non antiarrhythmic drugs: questions and answers (R3): guidance for industry. Food and Drug Administration, Silver Spring, MD. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM073161.pdf."},{"key":"e_1_3_2_8_2","volume-title":"Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-anti-arrhythmic drugs, October 2005.","author":"Food and Drug Administration","year":"2005","unstructured":"Food and Drug Administration. 2005. Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-anti-arrhythmic drugs, October 2005. Food and Drug Administration, Rockville, MD. https:\/\/www.fda.gov\/media\/71372\/download."},{"key":"e_1_3_2_9_2","volume-title":"Microbe 2018.","author":"Citron DM","year":"2018","unstructured":"Citron DM, Tyrrell KL, Rubio A, Goldstein EJC. 2018. In vitro activity of tebipenem (SPR859), tebipenem-pivoxil (SPR994) and meropenem against a broad spectrum of anaerobic bacteria, abstr SUN-559. Microbe 2018. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02181-18"},{"key":"e_1_3_2_11_2","volume-title":"Microbe 2018.","author":"Mendes RE","year":"2018","unstructured":"Mendes RE, Rhomberg PR, Huynh H, Cotroneo N, Rubio A, Flamm RK. 2018. Antimicrobial activity of tebipenem (SPR859) against a global challenge set, abstr SUN-558. Microbe 2018. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_12_2","volume-title":"Microbe 2018.","author":"Mendes RE","year":"2018","unstructured":"Mendes RE, Rhomberg PR, Watters A, Cotroneo N, Rubio A, Flamm RK. 2018. Antimicrobial activity assessment of tebipenem (SPR859) against an isolate collection causing urinary tract infections, abstr SUN-560. Microbe 2018. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_13_2","volume-title":"Microbe 2018.","author":"Zou Y","year":"2018","unstructured":"Zou Y, Cotroneo N, Rubio A. 2018. In vitro bactericidal activity and post-antibiotic effect of tebipenem (SPR859) against susceptible and extended-spectrum beta-lactamase producing Enterobacteriaceae as compared to levofloxacin (LVX) and meropenem (MEM), abstr SUN-561. Microbe 2018. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_14_2","volume-title":"ESCMID\/ASM Conference, Lisbon, Portugal.","author":"Johnson A","year":"2018","unstructured":"Johnson A, Farrington N, McEntee L, Kirby A, Melnick D, Rubio A, Utley L, Parr T, Hope W, Das S. 2018. Pharmacokinetics and pharmacodynamics of tebipenem (SPR859) for multi-drug resistant Enterobacteriaceae in a hollow fibre infection model, poster L2. ESCMID\/ASM Conference, Lisbon, Portugal. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00603-19"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00618-19"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1959-z"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1496821"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa515.1900"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0325-5"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13436"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00145-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00145-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:08:01Z","timestamp":1645484881000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00145-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6,17]]}},"alternative-id":["10.1128\/AAC.00145-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00145-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2021-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00145-21"}}